Cyclo Therapeutics, Inc. (CYTH)

$1.38

+0.14 (+11.29%)
Rating:
Recommendation:
-
Symbol CYTH
Price $1.38
Beta -0.505
Volume Avg. 0.04M
Market Cap 11.705M
Shares () -
52 Week Range 0.91-5.48
1y Target Est -
DCF Unlevered CYTH DCF ->
DCF Levered CYTH LDCF ->
ROE -25154997.79% Strong Sell
ROA -32655010.08% Strong Sell
Operating Margin -
Debt / Equity 51.23% Buy
P/E -0.76
P/B 1.59 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CYTH news


Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.